The Royal Marsden NHS Foundation Trust - Developmental Therapeutics Review - Q1 2011

Global Markets Direct, March 2011, Pages: 60

The Royal Marsden NHS Foundation Trust – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “The Royal Marsden NHS Foundation Trust – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by The Royal Marsden NHS Foundation Trust.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The Royal Marsden NHS Foundation Trust with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of The Royal Marsden NHS Foundation Trust’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in The Royal Marsden NHS Foundation Trust’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate The Royal Marsden NHS Foundation Trust’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of The Royal Marsden NHS Foundation Trust in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with The Royal Marsden NHS Foundation Trust.
- Avoid Intellectual Property Rights related issues.

List of Tables
List of Figures
The Royal Marsden NHS Foundation Trust Snapshot
The Royal Marsden NHS Foundation Trust Overview
Key Information
Key Facts
The Royal Marsden NHS Foundation Trust – Research and Development Overview
Key Therapeutic Areas
The Royal Marsden NHS Foundation Trust – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
The Royal Marsden NHS Foundation Trust – Pipeline Products Glance
The Royal Marsden NHS Foundation Trust – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The Royal Marsden NHS Foundation Trust Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
The Royal Marsden NHS Foundation Trust – Drug Profiles
Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Phase II - Trial Details
Phase III - Trial Details
Gemcitabine + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Adiramycin + Cyclophosphamide + Pegfilgrastim
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab + Methylprednisolone
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab + Methyprednisolone
Product Description
Mechanism of Action
R&D Progress
cetuximab + capecitabine + oxaliplatin
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Adriamycin
Product Description
Mechanism of Action
R&D Progress
Eloxatin + Xeloda + Cetuximab + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Eloxatin + Xeloda + Radiotherapy
Product Description
Mechanism of Action
R&D Progress
epirubicin + capecitabine + cisplatin
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cisplatin + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Epirubicin + Cyclophosphamide + Pegfilgrastim
Product Description
Mechanism of Action
R&D Progress
Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Gemcitabine + Capecitabine + Tarceva + Avastin
Product Description
Mechanism of Action
R&D Progress
Lapatinib
Product Description
Mechanism of Action
R&D Progress
Methotrexate
Product Description
Mechanism of Action
R&D Progress
Navelbine + Epirubicin
Product Description
Mechanism of Action
R&D Progress
Navelbine + Mitozantrone
Product Description
Mechanism of Action
R&D Progress
Nilotinib
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Capecitabine + concurrent radiotherapy
Product Description
Mechanism of Action
R&D Progress
PEG Intron
Product Description
Mechanism of Action
R&D Progress
Pegylated Interferon + Interferon-alpha2a
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline +Vitamin E
Product Description
Mechanism of Action
R&D Progress
R-CHOP-B
Product Description
Mechanism of Action
R&D Progress
Triapine
Product Description
Mechanism of Action
R&D Progress
Gemcitabine+ Oxaliplatin + Glivec
Product Description
Mechanism of Action
R&D Progress
The Royal Marsden NHS Foundation Trust – Pipeline Analysis
The Royal Marsden NHS Foundation Trust – Pipeline Products by Therapeutic Class
The Royal Marsden NHS Foundation Trust - Pipeline Products By Target
The Royal Marsden NHS Foundation Trust – Pipeline Products by Route of Administration
The Royal Marsden NHS Foundation Trust – Pipeline Products by Molecule Type
The Royal Marsden NHS Foundation Trust – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013